Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCH 527123 in moderate to severe chronic obstructive pulmonary disease
ACTRN12610000345088Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of navarixin in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline in post-bronchodilator FEV1. Started Nov 2009; status: recruiting.
02
Drugs
navarixin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ACTRN12610000345088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000345088.